Generic Semaglutide

Generic semaglutide is the same active molecule found in Ozempic — a GLP-1 receptor agonist — sold without the brand name and at a much lower price. Canada's first interchangeable generics launched in May 2026, after Novo Nordisk's data exclusivity on semaglutide expired on January 4, 2026. The two established manufacturers are Apotex, which sells it as Apo-Semaglutide, and Dr. Reddy's Laboratories.

For patients paying out of pocket, this is the single biggest cost change in the Canadian GLP-1 market in years. The identical drug that costs $250 to $310 a month as brand Ozempic can be dispensed as a generic for as little as $88 a month at a warehouse pharmacy. Because generics are approved as interchangeable, a pharmacist can typically substitute the generic for a brand prescription unless your doctor has specified otherwise — though substitution rules vary slightly by province.

It is worth being precise about what generic semaglutide is approved for. Like Ozempic, its Health Canada label is for type 2 diabetes, not weight loss. Any use for weight management would be off-label and is a conversation to have with a licensed physician.

Semaglutide mimics GLP-1, a hormone the gut releases after eating. It prompts the pancreas to release insulin when blood sugar is high, slows how quickly the stomach empties, and acts on appetite-regulating areas of the brain. The net effect for many people is steadier blood sugar and a reduced appetite.

Because the generic contains the identical molecule at the same strengths as the brand, its clinical behaviour is designed to match. Generics in Canada must demonstrate bioequivalence to the reference product before Health Canada will approve them as interchangeable.

Generic semaglutide is a once-weekly injection given under the skin, using a prefilled pen. It is taken on the same day each week, with or without food. The dose your prescriber sets and any adjustments over time are strictly a medical decision — this page does not offer dosing guidance beyond the label-level fact that it is a weekly injection.

Two kinds of lower-cost semaglutide now exist in Canada, and the distinction matters when you read a pharmacy shelf. A true generic — Apo-Semaglutide from Apotex, and Dr. Reddy's version — is made by a different company after the originator's exclusivity lapsed. An authorized generic is the originator's own product sold under a plain name: Novo Nordisk launched Plosbrio, an authorized generic of Ozempic, alongside the independent generics.

More competition is on the way. Sandoz and Teva have semaglutide products under Health Canada review, and industry watchers expect additional launches through 2026 to push prices down further. Under the pan-Canadian Pharmaceutical Alliance (pCPA) framework, the maximum price public plans pay is set to drop toward roughly $80 once a third generic manufacturer is on the market — a useful signal of where cash prices may head next.